$12.31
+0.18
(+1.48%)▲
2.11%
Downside
Day's Volatility :2.82%
Upside
0.73%
39.56%
Downside
52 Weeks Volatility :51.78%
Upside
20.22%
Period | Evolus, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.12% | 6.5% | 0.0% |
6 Months | 1.59% | 7.1% | 0.0% |
1 Year | 55.12% | 9.8% | 0.0% |
3 Years | 13.47% | 14.2% | -20.2% |
Market Capitalization | 770.1M |
Book Value | $0.3 |
Earnings Per Share (EPS) | -1.04 |
Wall Street Target Price | 22.29 |
Profit Margin | -27.31% |
Operating Margin TTM | -12.38% |
Return On Assets TTM | -10.69% |
Return On Equity TTM | -472.61% |
Revenue TTM | 219.7M |
Revenue Per Share TTM | 3.82 |
Quarterly Revenue Growth YOY | 42.199999999999996% |
Gross Profit TTM | 92.7M |
EBITDA | -27.7M |
Diluted Eps TTM | -1.04 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.31 |
EPS Estimate Next Year | 0.19 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.05 |
What analysts predicted
Upside of 81.07%
Sell
Neutral
Buy
Evolus, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Evolus, Inc. | 12.94% | 1.59% | 55.12% | 13.47% | -31.27% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Evolus, Inc. | NA | NA | NA | -0.31 | -4.73 | -0.11 | NA | 0.3 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Evolus, Inc. | Buy | $770.1M | -31.27% | NA | -27.31% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Evolus, Inc.
Revenue is down for the last 2 quarters, 60.99M → 59.33M (in $), with an average decrease of 2.7% per quarter
Netprofit is down for the last 2 quarters, -11.83M → -13.10M (in $), with an average decrease of 10.8% per quarter
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 39.1%
Perceptive Advisors LLC
TANG CAPITAL MANAGEMENT LLC
BlackRock Inc
Morgan Stanley - Brokerage Accounts
Nantahala Capital Management, LLC
Vanguard Group Inc
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Organization | Evolus, Inc. |
Employees | 279 |
CEO | Mr. David Moatazedi |
Industry | Health Technology |
A Spac I Acquisition Corp
$12.31
+1.48%
Keyarch Acquisition Corp
$12.31
+1.48%
Connexa Sports Technologies Inc
$12.31
+1.48%
Us Value Etf
$12.31
+1.48%
First Wave Biopharma Inc
$12.31
+1.48%
Global X Msci Next Emerging
$12.31
+1.48%
Fat Projects Acquisition Corp
$12.31
+1.48%
Capital Link Global Fintech
$12.31
+1.48%
Applied Uv Inc
$12.31
+1.48%